Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | $15.00 | Outperform | Leerink Partners |
| 9/5/2024 | $5.00 | Neutral | H.C. Wainwright |
| 5/3/2024 | $26.00 | Overweight | Piper Sandler |
| 10/10/2023 | $10.00 | Buy | Ladenburg Thalmann |
| 8/25/2023 | $17.00 | Outperform | Oppenheimer |
| 6/22/2023 | $20.00 | Buy | Guggenheim |
| 6/14/2023 | $14.00 | Buy | Chardan Capital Markets |
| 5/24/2023 | $20.00 | Strong Buy | Raymond James |
Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025 Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of Scientific Advisory Board Cash, cash equivalents and investments of $188.4 million as of June 30, 2024, including $112.5 million from private placement executed in April 2024, anticipated to support operations as currently planned through 2027 Zura Bio Limited
Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in 2H 2024 Appointment of CEO, Robert Lisicki, underscores Zura Bio's commitment to building leading immunology company as we prioritize excellence in strategic development and scientific planning Outgoing Founder and CEO, Someit Sidhu, M.D., will continue as a Board Director to leverage institutional knowledge and provide continued support Cash position as of December 31, 2023 totaling $99.8 million in cash, cash equi
Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio's Clinical Development programs Executive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointments of Robert Lisicki as President and Chief Operating Officer, and Kiran Nistala, MBBS, PhD, as Executive Vice President Development and Chief Medical Officer, to the Executive Leadership Team. Mr. Lisicki will be responsible for developing an
Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria
Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress
Focused on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist for systemic sclerosis and hidradenitis suppurativa Experienced team building the next immunology leader Cash and cash equivalents of $113 million support development and operations through 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the second quarter ended June 30, 2023, and recent business highlights. "Zura Bio made great progress in the first half of 2023, and we look forward to advancing
SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
SC 13G - Zura Bio Ltd (0001855644) (Subject)
Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00
H.C. Wainwright initiated coverage of Zura Bio Limited with a rating of Neutral and set a new price target of $5.00
Piper Sandler initiated coverage of Zura Bio Limited with a rating of Overweight and set a new price target of $26.00
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-jump-at-least-300-says-piper-sandler/
Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:ZURA) with a Overweight.
These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Congress of Rheumatology (EULAR) 2024 in Vienna.
8-K - Zura Bio Ltd (0001855644) (Filer)
10-Q - Zura Bio Ltd (0001855644) (Filer)
8-K - Zura Bio Ltd (0001855644) (Filer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4/A - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17A and BAFF, for the treatment of systemic sclerosis (SSc) in adults. "Systemic sclerosis presents significant unmet needs, as current treatments largely target only its interstitial lung disease (ILD) component," said Robert Lisicki,
Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in two investor conferences in November. Conference Details: Event: Guggenheim Inaugural Healthcare Innovation Conference Details: Participating in a fireside chat on Tuesday, November 12, 2024, at 1:00 p.m. ET and hosting investor meetings in Boston, MA. Event: Jefferies London Healthcare Conference Details: Hosting investor meetings Thursday, November 21, 2024, in London, UK. Links for live webcasts and replays, if available, will be po